MOESM2 of Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

Ma, Linlin; Zhu, Min; Gai, Junwei; Li, Guanghui; Chang, Qing; Qiao, Peng; Cao, Longlong; Chen, Wanqing; Zhang, Siyuan; Wan, Yakun

doi:10.6084/m9.figshare.11598171.v1

12951_2020_571_MOESM2_ESM.docx (138.86 kB)

MOESM2 of Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

journal contribution

posted on 2020-01-14, 05:15 authored by Linlin Ma, Min Zhu, Junwei Gai, Guanghui Li, Qing Chang, Peng Qiao, Longlong Cao, Wanqing Chen, Siyuan Zhang, Yakun Wan

Additional file 2: Figure S2. The IHC staining of HuNb1-IgG4 on macrophage in lymphoma mouse model.

Funding

National Natural Science Foundation of China

History

Usage metrics

Journal of Nanobiotechnology

Keywords

CD47 Immunotherapy Nanobody Bispecific antibody

Licence

CC BY + CC0

MOESM2 of Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

Funding

National Natural Science Foundation of China

History

Usage metrics

Categories

Keywords

Licence

Exports